nivolumabrelatlimab sold brand name opdualag fixeddose combination medication use treat contains nivolumab programmed death blocking antibody relatlimab lymphocyte activation blocking given intravenous combination approved medical use united states march european union september us food drug administration fda considers firstinclass combination indicated first line treatment advanced unresectable metastatic melanoma people aged twelve years age july committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product opdualag intended treatment applicant medicinal product bristolmyers squibb pharma opdualag approved medical use european union september immune activation dostarlimab ibalizumab antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikinivolumabrelatlimab